Unexploited potential of risk factor treatment in patients with atherosclerotic cardiovascular disease

Tinka J. van Trier*, Marjolein Snaterse, Steven H.J. Hageman, Nienke Ter Hoeve, Madoka Sunamura, Eric P. Moll van Charante, Henrike Galenkamp, Jaap W. Deckers, Fabrice M.A.C. Martens, Frank L.J. Visseren, Wilma J.M. Scholte Op Reimer, Ron J.G. Peters, Harald T. Jørstad

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

7 Downloads (Pure)

Abstract

BACKGROUND: Most patients with atherosclerotic cardiovascular disease remain at (very) high risk for recurrent events due to suboptimal risk factor control. AIMS: This study aimed to quantify the potential of maximal risk factor treatment on 10-year and lifetime risk of recurrent atherosclerotic cardiovascular events in patients 1 year after a coronary event. METHODS AND RESULTS: Pooled data from six studies are as follows: RESPONSE 1, RESPONSE 2, OPTICARE, EUROASPIRE IV, EUROASPIRE V, and HELIUS. Patients aged ≥45 years at ≥6 months after coronary event were included. The SMART-REACH score was used to estimate 10-year and lifetime risk of recurrent atherosclerotic cardiovascular events with current treatment and potential risk reduction and gains in event-free years with maximal treatment (lifestyle and pharmacological). In 3230 atherosclerotic cardiovascular disease patients (24% women), at median interquartile range (IQR) 1.1 years (1.0-1.8) after index event, 10-year risk was median (IQR) 20% (15-27%) and lifetime risk 54% (47-63%). Whereas 70% used conventional medication, 82% had ≥1 drug-modifiable risk factor not on target. Furthermore, 91% had ≥1 lifestyle-related risk factor not on target. Maximizing therapy was associated with a potential reduction of median (IQR) 10-year risk to 6% (4-8%) and of lifetime risk to 20% (15-27%) and a median (IQR) gain of 7.3 (5.4-10.4) atherosclerotic cardiovascular disease event-free years. CONCLUSIONS: Amongst patients with atherosclerotic cardiovascular disease, maximizing current, guideline-based preventive therapy has the potential to mitigate a large part of their risk of recurrent events and to add a clinically important number of event-free years to their lifetime.

Original languageEnglish
Pages (from-to)601-610
Number of pages10
JournalEuropean journal of preventive cardiology
Volume30
Issue number7
DOIs
Publication statusPublished - 9 May 2023

Keywords

  • Cardiovascular risk factors
  • Lifetime risk
  • Residual risk
  • Risk stratification
  • Secondary prevention

Fingerprint

Dive into the research topics of 'Unexploited potential of risk factor treatment in patients with atherosclerotic cardiovascular disease'. Together they form a unique fingerprint.

Cite this